You are viewing: Australia Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Australia Plasma Fractionation Market was valued at $704.7 Million in 2026 and projected to reach to $1055.5 Million by 2031, representing a compound annual growth rate of 8.4%. Australia's plasma fractionation market is positioned for sustained growth through 2031, driven by demographic shifts and healthcare modernization.

Australia Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Plasma Fractionation Market Trends and Insights

  • This expansion reflects Australia's strengthening healthcare infrastructure and increasing demand for immunoglobulin therapies, albumin products, and clotting factor concentrates.
  • Australia's aging population and rising prevalence of immunodeficiency disorders are driving adoption of plasma-derived therapeutics across hospitals and specialty clinics. The Australian market benefits from stringent regulatory frameworks and advanced manufacturing capabilities that ensure product safety and efficacy.
  • Australia's participation in global plasma supply chains and domestic collection initiatives supports consistent product availability.
  • Between 2026 and 2031, Australia is expected to witness accelerated growth driven by expanded reimbursement policies, increased clinical awareness, and investment in plasma collection infrastructure. Australia's plasma fractionation sector is positioned as a critical component of the Asia Pacific region's broader therapeutic landscape, with local manufacturers and international suppliers competing to meet rising patient demand for life-saving plasma-derived medicines..

Key Market Statistics

  • CAGR (2026-2031) 8.4% CAGR
  • Market Size, 2026 ~USD 704.7 Million
  • Forecast, 2031 ~USD 1055.5 Million
  • Country Australia

Australia Plasma Fractionation Market Overview

Market Valuation Growth :

Australia's plasma fractionation market is valued at USD 704.7 million in 2026 and is projected to reach USD 1,055.5 million by 2031, representing a robust 8.4% CAGR over the forecast period.

Aging Population Dynamics :

Australia's rapidly aging demographic is driving increased demand for immunoglobulin therapies, albumin products, and clotting factor concentrates, key plasma-derived therapeutics for age-related conditions.

Healthcare Infrastructure Expansion :

Strengthening healthcare infrastructure across Australia, including improved hospital networks and diagnostic capabilities, is enhancing access to plasma fractionation products and supporting market penetration.

Immunological Disease Prevalence :

Rising prevalence of immunological disorders and bleeding disorders in Australia is creating sustained demand for specialized plasma fractionation therapies and driving market expansion.

Australia Plasma Fractionation Market Dynamics

  • The country's aging population increasingly requires immunoglobulin therapies and clotting factors, while improved healthcare infrastructure ensures better product accessibility.
  • Government support for biopharmaceutical development and strong regulatory frameworks create a favorable environment for market expansion.
  • Australia's focus on self-sufficiency in plasma collection and fractionation capabilities will further strengthen the market, with domestic manufacturers gaining competitive advantages in meeting local demand for critical blood-derived therapeutics..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Australia's plasma fractionation market will grow from USD 704.7M (2026) to USD 1,055.5M (2031) at an 8.4% CAGR, outpacing global growth.
      • Australia's aging demographic and rising immunodeficiency prevalence are primary drivers of increased plasma-derived therapeutic demand.
      • Australia's robust regulatory environment and manufacturing infrastructure position the country as a reliable regional supplier and market.
      • Expanded reimbursement policies and plasma collection investments in Australia will accelerate market expansion through 2031.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Australia Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies need Australia-specific market data to assess expansion opportunities, competitive positioning, and demand forecasts for immunoglobulin and albumin products in this high-growth market.
      • Healthcare Investors : Investment firms require detailed Australian market valuations and growth projections to evaluate portfolio opportunities in the biopharmaceutical sector and identify high-potential acquisition targets.
      • Hospital & Clinical Networks : Australian healthcare providers need market intelligence on plasma fractionation product availability, pricing trends, and supply chain dynamics to optimize procurement and patient care delivery.
      • Regulatory & Policy Bodies : Government agencies and health authorities require market data to inform policy decisions, plasma collection strategies, and self-sufficiency initiatives for critical blood-derived therapeutics.
      • Medical Device Distributors : Local and regional distributors need Australia-specific market forecasts and demand drivers to plan inventory, negotiate supplier contracts, and identify growth segments in plasma fractionation.

      Reasons to Buy this Report

      • Precise Market Sizing : Access validated market valuations specific to Australia (USD 704.7M in 2026, USD 1,055.5M in 2031) with country-specific CAGR of 8.4%, enabling accurate financial forecasting and investment planning.
      • Demographic Insights : Understand Australia's aging population dynamics and their direct impact on demand for immunoglobulin therapies, albumin, and clotting factors, informing product development and market entry strategies.
      • Competitive Landscape Analysis : Gain intelligence on Australia's domestic plasma fractionation capabilities, regulatory environment, and competitive positioning to identify market opportunities and partnership potential.
      • Healthcare Infrastructure Assessment : Evaluate Australia's strengthening healthcare infrastructure, hospital networks, and distribution channels to optimize market penetration strategies and supply chain planning.
      • Strategic Market Entry : Leverage country-specific growth drivers and market trends to develop targeted go-to-market strategies, pricing models, and regulatory compliance approaches for the Australian market.

      Frequently asked questions

      What is the current size of Australia's plasma fractionation market?

      Australia's plasma fractionation market is valued at USD 704.7 million in 2026 and is projected to reach USD 1,055.5 million by 2031.

      What is the growth rate of Australia's plasma fractionation market?

      Australia's plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2031.

      What factors are driving growth in Australia's plasma fractionation market?

      Key drivers include Australia's aging population, rising immunodeficiency disorder prevalence, expanded reimbursement policies, and increased investment in plasma collection infrastructure.

      Which plasma-derived products are most in demand in Australia?

      Australia shows strong demand for immunoglobulin therapies, albumin products, and clotting factor concentrates across hospitals and specialty clinics.

      How does Australia's regulatory environment impact the plasma fractionation market?

      Australia's stringent regulatory frameworks and advanced manufacturing capabilities ensure product safety and efficacy, supporting market confidence and international competitiveness.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status